The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

After pathology and CT review ... viewarticle/408749 Endoscopic view of left nasal cavity showing polyposis in middle meatus. Notice how the polyps exhibit a glistening, almost translucent ...

Since tau tangles and amyloid plaques are hallmarks of AD, it is thought treating both could be of more benefit to patients, as opposed to targeting a single pathology. Compared to controls ...

This case serves to highlight a systematic approach to evaluating a unilateral nasal mass and the clinical histopathological features of a rare, sinonasal pathology ... antrochoanal polyp, juvenile ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.